Aims: The MARLINA-T2D study (ClinicalTrials.gov, NCT01792518) was designed to investigate the glycaemic and renal effects of linagliptin added to standard-of-care in individuals with type 2 diabetes and albuminuria.
| INTRODUCTION
Approximately 35% to 40% of individuals with type 2 diabetes also have chronic kidney disease (CKD), 1,2 defined as albuminuria and/or reduced glomerular filtration rate (GFR). These individuals account for most of the excess risk of premature death seen in the overall type 2 diabetes population. 3 Moreover, each renal marker independently predicts the risk of CKD progression, as well as adverse cardiovascular outcomes. [4] [5] [6] [7] [8] [9] [10] The current standard of care for individuals with type 2 diabetes and CKD includes individualized glycaemic control and single agent renin-angiotensin-aldosterone system (RAAS) blockade with either angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs). 11, 12 However, individuals with residual albuminuria despite treatment with RAAS blockers still remain at substantial risk for cardio-renal morbidity and mortality. 13 This high residual risk is driving the search for novel therapies to treat diabetic kidney disease.
Dipeptidyl peptidase-4 (DPP-4) inhibitors are now embedded in the therapeutic armamentarium as suitable options for managing hyperglycaemia in individuals with type 2 diabetes across the full range of CKD stages. 14 DPP-4 is expressed in many tissues and organs, with the highest levels found in the kidney. 15 Several preclinical studies have suggested that targeting kidney DPP-4 with the high-affinity inhibitor linagliptin may have direct (ie, non-glycaemic) renoprotective effects. [16] [17] [18] [19] The hypothesis of a direct renal effect of linagliptin was further supported by a pooled analysis of 4 pivotal phase 3 clinical trials. Herein, treatment with linagliptin for 24 weeks was associated with a statistically significant and clinically relevant 28% reduction in albuminuria compared with placebo in type 2 diabetes patients with renal dysfunction who were already receiving ACE inhibitors or ARBs; this effect appeared to be independent of the concomitant improvements in glycaemic control. 20 Furthermore, a pooled analysis of 13 randomized clinical trials found that linagliptin treatment of up to 12 to 76 weeks was associated with a statistically significant and clinically relevant 16% reduction in the risk of progression of CKD. 21 Based on these observations, 2 independent hypotheses were advanced: first, linagliptin may acutely reduce glomerular damage, thus reducing prevalent albuminuria; second, linagliptin may slow the progression of CKD over the long term. 2 | METHODS
| Study design and participants
The design and methodology of MARLINA-T2D has been previously reported in detail. 22 MARLINA-T2D was a 24-week, randomized, 
| Procedures and endpoints

| Statistical analyses
The required sample size (350 participants, 175 per treatment arm) was calculated as previously described, 22 and was intended to provide 99% power to detect a significant difference (α = 0.05, two-sided), assuming a 0.6% (6.6 mmol/mol) difference, in change in HbA1c from baseline after 24 weeks between treatment groups and 87% power to detect a treatment ratio of 0.79 in the ratio of UACR change from baseline. 22 The primary and key secondary endpoints were tested in a (Table S1 ). The percentage of participants with baseline HbA1c ≥7.0% who achieved HbA1c <7.0% at week 24 was analysed post hoc using a logistic regression model in which treatment was a factor and continuous baseline HbA1c and continuous baseline log10 (UACR) were covariates.
The key secondary endpoint was evaluated using an analysis of covariance (ANCOVA) of data from the FAS, with baseline HbA1c and baseline log10 (UACR) as linear covariates and treatment as a fixed classification effect; the last-observation-carried-forward (LOCF) approach was used to replace missing data (including values obtained after glycaemic rescue therapy was started). Because of their non-normal distribution, UACR data were log10-transformed prior to ANCOVA analyses. Similar ANCOVA models were performed for subgroup analyses, including a post hoc analysis by background therapy at baseline (ACE inhibitors or ARBs) ( Table S2 ).
The odds of achieving a clinically relevant UACR response with linagliptin compared with placebo at week 24 were analysed post hoc using a logistic regression model. In this analysis, the linagliptin and placebo groups were compared for the proportion of participants with a UACR response at week 24, defined as a reduction in UACR of >20% at week 24 relative to baseline, vs those with no UACR response, defined as no change or an increase in UACR at week 24 compared to baseline. This analysis was performed on the FAS and included eligible participants with a UACR value at week 24, irrespective of introduction of glycaemic rescue therapy (OC-ROC). The logistic regression model contained treatment as a factor and continuous baseline HbA1c and continuous baseline log10 (UACR) as covariates.
Safety analyses were generally performed using descriptive summaries of adverse events in the treated set (all randomized participants who received at least 1 dose of study drug). Change from baseline in eGFR (CKD-EPI, cystatin C) in the treated set was analysed using the MMRM for the primary endpoint, with baseline eGFR and baseline eGFR by visit as additional terms.
| RESULTS
A total of 360 participants were randomized to linagliptin (n = 182) or placebo (n = 178) and comprised the treated set. The FAS consisted of 180 participants in the linagliptin-treated group and 174 in the placebo-treated group. Participant disposition is shown in Figure S1 .
Baseline demographic and clinical characteristics were generally similar between treatment groups ( 
| Efficacy
The Figure 2C , Figure S3 ). Post hoc analysis revealed no significant difference in change from baseline in UACR between participants receiving either an ACE inhibitor or ARB as background therapy:
placebo-corrected adjusted gMean ratios of −14% (95% CI (Figure 3 ).
| Tolerability
A summary of adverse events is shown in Table S3 . Adverse events were reported by 107 participants in both the linagliptin and placebo groups (58.8% and 60.1%, respectively), but few were deemed by investigators to be related to the study drug (13 [7. 1%] and 11 [6.2%] participants, respectively). Adverse events leading to discontinuation of the study drug occurred in 3 linagliptin-treated participants (1.6%) and in 2 placebo-treated participants (1.1%). Serious adverse events occurred in 17 participants treated with linagliptin and in 8 receiving placebo (9.3% and 4.5%, respectively); these included 2 deaths in the linagliptin group (1.1%) and 1 death in the placebo group (0.6%). Serious adverse events reported in linagliptin-treated participants were related to different acute and chronic medical conditions rather than any single condition.
Investigator-reported hypoglycaemia occurred in 24 linagliptintreated participants (13.2%) and in 10 participants receiving placebo (5.6%), mostly in those receiving concomitant treatment with a sulphonylurea or insulin (Table S3) ; however, no severe hypoglycaemic episodes occurred. Apart from hypoglycaemia, the most common individual adverse events associated with linagliptin treatment were nasopharyngitis (7.1% and 5.6% of the linagliptin and placebo groups, respectively), hyperglycaemia (4.9% and 4.5%, respectively) and hyperuricaemia (4.4% and 1.7%, respectively) (Table S3) .
CEC-confirmed cardiovascular events occurred in 3 linagliptintreated participants (1.6%) and in no participants receiving placebo.
CEC-confirmed pancreatitis occurred in 1 linagliptin-treated participant (0.5%) and in 2 participants receiving placebo (1.1%). No cases of pancreatic cancer occurred in either treatment group. No participant was hospitalized for heart failure.
No new cases of end-stage kidney disease occurred during the study. Adjusted mean AE SE difference in change from baseline in eGFR (CKD-EPI, cystatin C) at week 24 between the linagliptin and placebo groups was −2.63 AE 2.70 mL/min/1.73 m 2 (P = .3306). There was also no significant difference in mean change in eGFR between the linagliptin and placebo groups at weeks 6, 12 and 18 ( Figure S4 ).
Ambulatory blood pressure monitoring at baseline and week 24 indicated that blood pressure remained stable during treatment, with no significant difference in mean change between the linagliptin and placebo groups. 23 
| DISCUSSION
In the MARLINA-T2D study reported here, linagliptin significantly improved glycaemic control in type 2 diabetes patients with prevalent Abbreviations: ACE, angiotensin-converting enzyme; ARBs, angiotensin II receptor blockers; BMI, body mass index; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; FAS, full analysis set; gCV, geometric coefficient of variation; gMean, geometric mean; HbA1c, glycated haemoglobin; MDRD, modification of diet in renal disease; SD, standard deviation; UACR, urinary albumin-to-creatinine ratio.
Data are presented as mean AE SD unless otherwise stated.
a FAS (linagliptin, n = 180; placebo, n = 174).
b Baseline UACR values were defined as the gMean of samples taken on 3 consecutive days immediately before the placebo run-in and the day before randomization; these patients were eligible based on having UACR >30 mg/g at screening and gMean UACR >30 mg/g for samples taken on 3 consecutive days immediately before the placebo run-in. In general, it is likely that ubiquitous albuminuria-lowering effects over the short term may be achieved only by haemodynamic interventions that actively lower glomerular pressure, such as RAAS blockers and, possibly, SGLT2 inhibitors such as empagliflozin, 31 dapagliflozin 32 or canagliflozin. 33 The small mean reduction in albuminuria (−5.1%) in the placebo group probably reflects regression to the mean, given the absence of meaningful changes in blood pressure, kidney function and long-term glycaemia in this group.
Nevertheless, post hoc analysis of data from MARLINA-T2D
suggests that linagliptin may lower albuminuria to a meaningful extent (>20% in our judgement) in some patients; this cut-off was based on a meta-analysis of clinical trials reporting renal outcomes which found that an overall reduction in albuminuria of 19.2% was associated with a statistically significant 17% reduction in the rela- 43 This suggests a possibility that the MARLINA-T2D study population contained too few individuals with advanced CKD to fully unmask the anti-albuminuric effect of linagliptin. Finally, and importantly, MARLINA-T2D assessed a surrogate endpoint rather than actual renal outcomes.
In conclusion, the MARLINA-T2D study found that linagliptin improved glycaemic control in individuals with type 2 diabetes and early stages of diabetic kidney disease but did not significantly ameliorate acute glomerular damage overall, as estimated using the surrogate endpoint of albuminuria; albeit, significantly more participants in the linagliptin group than in the placebo group experienced a meaningful improvement in albuminuria. The long-term effect of linagliptin on hard renal outcomes remains to be determined in the ongoing CARMELINA study.
